Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

855
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
855
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

909
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

789
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

707
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
707
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Prospective Multicenter Evaluation of a Novel Active Driving System for Pediatric Ventricular Assist Device Support.

Journal of the American College of Cardiology·2026
Same author

Multicenter Registry Analysis of Bivalirudin for Primary Anticoagulation in Pediatric HeartMate 3 Recipients: ACTION Analysis.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Capturing Physiological Data in Children With Heart Failure Using Wearable Digital Technology: Lessons From Pilot Project.

CJC pediatric and congenital heart disease·2026
Same author

Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era.

Pediatric transplantation·2025
Same author

Authors Insights on the Updated International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014).

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Apr 15, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

20.4K

Ventrículo izquierdo cardiomiopatía sin compactación.

Jeffrey A Towbin1, Angela Lorts1, John Lynn Jefferies1

  • 1The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Lancet (London, England)
|April 14, 2015
PubMed
Resumen
Este resumen es generado por máquina.

La no compactación ventricular izquierda (LVNC) es una cardiomiopatía rara con un desarrollo anormal del músculo cardíaco. Los factores genéticos y las vías alteradas contribuyen a riesgos que incluyen insuficiencia cardíaca, arritmias y muerte súbita.

Más Videos Relacionados

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

Videos de Experimentos Relacionados

Last Updated: Apr 15, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

20.4K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

Área de la Ciencia:

  • Cardiología Cardiología.
  • Genética La genética.
  • Biología Molecular Biología Molecular

Sus antecedentes:

  • La no compactación ventricular izquierda (LVNC) es una cardiomiopatía recientemente clasificada.
  • Se caracteriza por trabeculaciones ventriculares izquierdas anormales, a menudo asociadas con disfunción cardíaca y enfermedad cardíaca congénita.
  • Los pacientes se enfrentan a riesgos de insuficiencia cardíaca, arritmias y muerte súbita, con factores genéticos implicados en el 30-50% de los casos.

Objetivo del estudio:

  • Para resumir el entendimiento actual de la no compactación ventricular izquierda (LVNC).
  • Para resaltar la base genética, la fisiopatología y las manifestaciones clínicas de LVNC.
  • Revisar las estrategias terapéuticas actuales y necesarias para los pacientes con LVNC.

Principales métodos:

  • Revisión de la literatura de los estudios sobre la no compactación ventricular izquierda (LVNC).
  • Análisis de asociaciones genéticas, incluidas las proteínas sarcoméricas y citoesqueléticas.
  • Examen de la vía de señalización NOTCH y la disfunción mitocondrial en la patogénesis de LVNC.

Principales resultados:

  • LVNC implica un desarrollo ventricular anormal, lo que lleva a diversos problemas cardíacos.
  • Las mutaciones genéticas en las proteínas contráctiles o citoesqueléticas son causas comunes.
  • La interrupción de la señalización NOTCH y la disfunción mitocondrial juegan un papel, particularmente con las enfermedades cardíacas congénitas.

Conclusiones:

  • LVNC presenta resultados clínicos variados, desde asintomáticos hasta insuficiencia cardíaca grave.
  • La gestión se centra en mejorar la función cardíaca, controlar las arritmias y prevenir la muerte súbita.
  • Se necesita más investigación para mejorar la comprensión y los resultados para los pacientes con LVNC.